Current And Emerging Agents For Tinea Pedis
- Volume 27 - Issue 4 - April 2014
- 4300 reads
- 0 comments
Using a commercial ultraviolet shoe sanitizer (SteriShoe, Shoe Care Innovations) with an ultraviolet C lamp, Ghannoum and coworkers first optimized a model of infecting shoes and recovering the dermatophyte, and showed the efficacy of the device to reduce fungal burden in the same footgear.17 After researchers applied one treatment cycle (45 minutes) of the ultraviolet C shoe sanitizer to the fungally infected shoes in comparison to the growth controls, 88.8 percent of T. rubrum was eradicated along with 83.9 percent of T. mentagrophytes. Researchers applied a second and third cycle of the shoe sanitizer to the shoes, but ultimately, the study showed that the reduction of fungal growth with one treatment cycle is satisfactory.
By addressing the footwear, this ultraviolet C shoe sanitizer has the potential to break the infection cycle in our patients by providing a simple daily protocol. Certainly, future studies using this device in patient-worn shoes will provide an even more compelling argument in recommending this to patients who suffer from recurrent tinea pedis.
These new innovations are exciting additions to the fungal treatment armamentarium. They show the commitment of industry in helping podiatric physicians to not only treat tinea with greater patient adherence (a two-week treatment regimen versus four weeks), but also to effectively assist in reducing recurrence by addressing socks and shoes.
Dr. Vlahovic is an Associate Professor and J. Stanley and Pearl Landau Fellow at the Temple University School of Podiatric Medicine in Philadelphia. She is a Fellow on the Faculty of Podiatric Medicine at the Royal College of Physicians and Surgeons in Glasgow, Scotland.